N-M-Tolylcinnamamide

N-M-Tolylcinnamamide

SCHEMBL1601210

Cc1cccc(NC(=O)C=Cc2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 11/20 1.00
MMP2 P08253 11/20 1.00
MMP9 P14780 11/20 1.00
MAOB P27338 6/20 1.00
EGFR P00533 6/20 1.00
MAOA P21397 5/20 1.00
MAPT P10636 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
MEN1 O00255 1/20 0.68
NPC1 O15118 1/20 0.68
ALPG P10696 1/20 0.68
RAB9A P51151 1/20 0.68
KMT2A Q03164 1/20 0.68
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-M-Tolylcinnamamide SCHEMBL3732520 1.00 MMP1 (1.00) MMP1MMP2MMP9MAOBEGFR
N-M-Tolylcinnamamide SCHEMBL3732518 1.00 MMP1 (1.00) MMP1MMP2MMP9MAOBEGFR
SCHEMBL26458454 0.87 MMP1 (0.78) MMP1MMP2MMP9MAOBEGFR
SCHEMBL15708841 0.85 MMP1 (0.73) MMP1MMP2MMP9MAOBEGFR
SCHEMBL15708460 0.85 MMP1 (0.73) MMP1MMP2MMP9MAOBEGFR
SCHEMBL15708843 0.85 MMP1 (0.73) MMP1MMP2MMP9MAOBEGFR
SCHEMBL3590876 0.85 MMP1 (0.74) MMP1MMP2MMP9MAOBEGFR
SCHEMBL3590874 0.85 MMP1 (0.74) MMP1MMP2MMP9MAOBEGFR
SCHEMBL13675776 0.85 MMP1 (0.74) MMP1MMP2MMP9MAOBEGFR
SCHEMBL8058291 0.85 MMP1 (0.73) MMP1MMP2MMP9MAOBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111217694-B Method for selectively reducing carbon-carbon double bond in alpha, beta-unsaturated carbonyl compound 五邑大学 2022-09-30 CN disclosed
US-9783500-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-10-10 US disclosed
US-9663468-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-05-30 US disclosed
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160096806-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-04-07 US disclosed
US-9212144-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2015-12-15 US disclosed
US-20150210644-A1 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION NORTHWESTERN UNIVERSITY 2015-07-30 US disclosed
US-8569282-B2 Carboxamide compounds and their use CYTOPATHFINDER, INC. (JP) 2013-10-29 US disclosed
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 US disclosed
US-7919621-B2 Tricyclic inhibitors of 5-lipoxygenase AMIRA PHARMACEUTICALS, INC. (US) 2011-04-05 US disclosed
US-20100324035-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-23 US disclosed
US-20100286136-A1 DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS JONES SIMON 2010-11-11 US disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286136-A1 DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS ALDH1A2, QDPR, PDE6C MMP1 1957/4885MMP2 1030/4885MMP9 1112/4885
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B MMP1 1457/4885MMP2 1276/4885MMP9 953/4885
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B MMP1 1457/4885MMP2 1276/4885MMP9 953/4885
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NOS2, NOS3, NOS1 MMP1 4426/4885MMP2 2465/4885MMP9 3081/4885
US-20150210644-A1 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION NOS2, NOS3, NOS1 MMP1 4426/4885MMP2 2465/4885MMP9 3081/4885
US-20100324035-A1 Carboxamide Compounds and Their Use CCR2, CCR1, CCR5 MMP1 672/4885MMP2 1767/4885MMP9 2551/4885
US-20160096806-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NOS2, NOS3, NOS1 MMP1 4426/4885MMP2 2465/4885MMP9 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.